Business
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
BOSTON, November 12, 2025--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
About this update from Biocryst Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3945,"height":1189,"url":"https://media.zenfs.com/en/business-wire.com/c3f643a3826667b32ab4f1ed0af87b8d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/F_W9H6DyNhJcj8aI4RzLBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c3f643a3826667b32ab4f1ed0af87b8d","width":960,"height":289},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NBiJK3R0p6zGZkqRPFR6GQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MjQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c3f643a3826667b32ab4f1ed0af87b8d","width":1200,"height":362}},"lazy":false},{"type":"text","content":"-- BioCryst’s Acquisition of Astria Expected to Close in the First Quarter of 2026 --","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"-- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with Topline Results Anticipated in Early 2027; First Patient Now Enrolled in the ORBIT-EXPANSE Long-Term Extension Trial --","length":194,"tagName":"p","attribs":{}},{"type":"text","content":"-- Final Phase 1b/2 ALPHA-STAR Results in 29 HAE Patients Reinforces Navenibart’s Robust HAE Attack Prevention and Favorable Safety Profile --","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"-- STAR-0310, an OX40 Antagonist, Demonstrated a Best-In-Class Profile with Initial Phase 1a Data Presented at the European Academy of Dermatology and Venereology Congress --","length":174,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, November 12, 2025--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.","length":311,"tagName":"p"},{"type":"text","content":""We believe that the proposed transaction with BioCryst provides the best opportunity to advance navenibart, enabling people with HAE to potentially live free from the limitations of their disease," said Jill C. Milne, Ph.D., CEO of Astria Therapeutics. "We also believe the acquisition represents a compelling outcome for Astria stockholders, providing cash for their shar...